Goeltz II Robert C.

Average Profitability
33.11%
Insider Buys Quantity
1
Insider Buys Sum
$107,848.50
Insider Sells Quantity
6
Insider Sells Sum
$1.09M

Insider Activity of Goeltz II Robert C.

According to the SEC Form 4 filings, Goeltz II Robert C., being in a position of

  1. Chief Financial Officer at Arcus Biosciences, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 2004 shares for $40,080,
    over all time since 2020-09-09, has bought 5000 shares for $107,849, and sold 9612 shares for $241,028.

The largest purchase of all time was on 2020-09-09 and amounted to 5000 shares of Arcus Biosciences, Inc. for $107,849.

The largest sale of all time was on 2017-03-20 and amounted to 43034 shares of CytomX Therapeutics, Inc. for $852,680.

Biography of Goeltz II Robert C.

No biography is available at this moment.

2024-01-02SaleArcus Biosciences, Inc.
RCUS
Chief Financial Officer
2,004
0.0027%
$20.00$40,080-15.96%
2023-06-07SaleArcus Biosciences, Inc.
RCUS
Chief Financial Officer
4,049
0.0054%
$20.04$81,142-15.94%
2022-12-16SaleArcus Biosciences, Inc.
RCUS
Chief Financial Officer
2,453
0.0034%
$30.75$75,430-39.59%
2021-12-17SaleArcus Biosciences, Inc.
RCUS
Chief Financial Officer
621
0.0009%
$40.36$25,061-33.15%
2021-12-16SaleArcus Biosciences, Inc.
RCUS
Chief Financial Officer
485
0.0007%
$39.83$19,315-29.33%
2020-09-09PurchaseArcus Biosciences, Inc.
RCUS
Chief Financial Officer
5,000
0.0079%
$21.57$107,849+33.11%
2017-03-20SaleCytomX Therapeutics, Inc.
CTMX
Chief Financial Officer
43,034
0.1235%
$19.81$852,680-6.3%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.